updated 11/3/2010 12:15:29 AM ET 2010-11-03T04:15:29

WARRINGTON, Pa., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it will be hosting a conference call on Tuesday, November 9, 2010, at 10:00 AM EST. Management will provide a pipeline and business update addressing:

  • Status of program to gain FDA approval for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants
  • Status of key pipeline programs including: additional data analysis from the recently completed comprehensive analysis of the Phase 2 clinical trial of Surfaxin in children with Acute Respiratory Failure (ARF); review of recently completed Phase 2a clinical study of aerosolized KL4 surfactant in patients with cystic fibrosis (CF); update of next generation RDS programs – Surfaxin LS™ and Aerosurf®
  • Strategic initiatives and financial overview

Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com . The webcast is also accessible on the Internet: http://us.meeting-stream.com/discoverylabs_110910 . It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at both website addresses.

The call in number is 866-332-5218. The international call in number is 706-679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through November 16, 2010. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 22279770.

About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases.  Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com .

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com